AXIM (AXIM Biotechnologies) 3-1 Month Momentum %: -23.71% (As of Jul. 11, 2026)


What is AXIM Biotechnologies 3-1 Month Momentum %?

AXIM Biotechnologies AXIM -14.63% 3-1 Month Momentum % is -23.71% as of Jul. 11, 2026. Among 1,385 Biotechnology companies, AXIM Biotechnologies ranks worse than 71.48% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-11), AXIM Biotechnologies's 3-1 Month Momentum % is -23.71%.

The industry rank for AXIM Biotechnologies's 3-1 Month Momentum % or its related term are showing as below:

AXIM's 3-1 Month Momentum % is ranked worse than
71.48% of 1385 companies
in the Biotechnology industry
Industry Median: -10.98 vs AXIM: -23.71

AXIM Biotechnologies  (OTCPK:AXIM) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

AXIM Biotechnologies 3-1 Month Momentum % Related Terms

AXIM vs ZVSA, HEPA, ISCO: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's 3-1 Month Momentum % falls into.


AXIM Biotechnologies  (OTCPK:AXIM) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -23.71% mean?
AXIM Biotechnologies (AXIM) has a 3-1 Month Momentum % of -23.71% as of Jul. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #990 out of 1385 companies in the Biotechnology industry, placing it in the top 71.5%.
Is AXIM Biotechnologies' 3-1 Month Momentum % too high?
AXIM Biotechnologies' current 3-1 Month Momentum % is -23.71%. Based on the distribution chart, AXIM Biotechnologies ranks #990 out of 1385 companies in the Biotechnology industry, which is below the industry midpoint.
How does AXIM Biotechnologies' 3-1 Month Momentum % compare to ZVSA and HEPA?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #990 out of 1385 companies for 3-1 Month Momentum %. This places AXIM Biotechnologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current 3-1 Month Momentum % is -23.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current 3-1 Month Momentum % of -23.71%. The current 3-1 Month Momentum % is -23.71%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current 3-1 Month Momentum % is -23.71% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.